NERV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Minerva Neurosciences Inc (NERV) is not a strong buy at this time for a beginner investor with a long-term focus. The technical indicators do not suggest a clear upward trend, and there are no significant positive catalysts or trading signals to support an immediate purchase. While the analyst rating reflects optimism with a price target increase, the company's financial performance remains weak, and there are no recent news or influential trades to indicate a strong buying opportunity.
The MACD is negative and expanding downward (-0.262), RSI is neutral at 27.779, and moving averages are converging. The stock is trading near its support level of 6.062, with resistance at 7.235. Overall, the technical indicators do not suggest a strong upward trend.
H.C. Wainwright raised the price target from $4 to $7, citing promising positioning of the new schizophrenia study for potential approval and additional funding.
No recent news, no significant hedge fund or insider trading trends, and no recent congress trading data. Financials show significant losses, with no revenue growth.
In Q4 2025, revenue remained at $0 (0% YoY growth), net income increased to -$283.67M (up 6540.09% YoY), and EPS improved to -25.45 (up 4444.64% YoY). Gross margin remained at 0%. Financials reflect significant losses despite some improvement in percentages.
H.C. Wainwright raised the price target to $7 from $4, maintaining a Neutral rating. The firm sees potential in the new schizophrenia study and additional funding as positive factors.
